Supporting Publications

NGR1 PATHWAY & MECHANISM 

REVIEWS
.
Nogo limits neural plasticity and recovery from injury.
Schwab ME, Strittmatter SM.  Curr Opin Neurobiol. 2014 Aug;27:53-60.

Extracellular regulators of axonal growth in the adult central nervous system.
Liu BP, Cafferty WB, Budel SO, Strittmatter SM. Philos Trans R Soc Lond B Biol Sci. 2006 Sep 29;361(1473):1593-610.
​​Anatomical plasticity of adult brain is titrated by Nogo Receptor 1.
Akbik FV, Bhagat SM, Patel PR, Cafferty WB, Strittmatter SM. Neuron. 2013 Mar 6;77(5):859-66.

Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity.
Akbik F, Cafferty WB, Strittmatter SM. Exp Neurol. 2012 May;235(1):43-52.

MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma.
Cafferty WB, Duffy P, Huebner E, Strittmatter SM. J Neurosci. 2010 May 19;30(20):6825-37.

Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin.
Fournier AE, Gould GC, Liu BP, Strittmatter SM. J Neurosci. 2002 Oct 15;22(20):8876-83.

Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. 
Liu BP, Fournier A, GrandPré T, Strittmatter SM. Science. 2002 Aug 16;297(5584):1190-3.

Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth.
Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, He Z. Nature. 2002 Jun 27;417(6892):941-4.

Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration.
Fournier AE, GrandPré T, Strittmatter SM. Nature. 2001 Jan 18;409(6818):341-6.

Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein.
GrandPré T, Nakamura F, Vartanian T, Strittmatter SM. Nature. 2000 Jan 27;403(6768):439-44.

OPHTHALMOLOGY

Glaucoma

Nogo receptor 1 is expressed by nearly all retinal ganglion cells.
Solomon AM, Westbrook T, Field GD, McGee AW. PLoS One. 2018 May 16;13(5).

Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models. 
Wang X, Lin J, Arzeno A, Choi JY, Boccio J, Frieden E, Bhargava A, Maynard G, Tsai JC, Strittmatter SM.  Invest Ophthalmol Vis Sci. 2015 Feb 5;56(2):1357-66. 

Soluble Nogo-66 receptor prevents synaptic dysfunction and rescues retinal ganglion cell loss in chronic glaucoma.
Fu QL, Liao XX, Li X, Chen D, Shi J, Wen W, Lee DH, So KF. Invest Ophthalmol Vis Sci. 2011 Oct 28;52(11):8374-80.

Counteracting the Nogo receptor enhances optic nerve regeneration if retinal ganglion cells are in an active growth state.
Fischer D, He Z, Benowitz LI. J Neurosci. 2004 Feb 18;24(7):1646-51.
Optic Neuritis

Limiting neuronal Nogo Receptor 1 signaling during experimental autoimmune encephalomyelitis preserves axonal transport and abrogates inflammatory demyelination.
Lee JY, Kim MJ, Thomas S, Oorschot V, Ramm G, Aui PM, Sekine Y, Deliyanti D, Wilkinson-Berka J, Niego B, Harvey AR, Theotokis P, McLean C, Strittmatter SM, Petratos S. J Neurosci. 2019 Jul 10;39(28):5562-5580.

Can we design a Nogo receptor-dependent cellular therapy to target MS?
Kim MJ, Kang JH, Theotokis P, Grigoriadis N, Petratos S. Cells. 2018 Dec 20;8(1):1.

​Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, Siatskas C, Litwak S, Fehlings MG, Strittmatter SM, Bernard CC. Brain. 2012 Jun;135(Pt 6):1794-818.
Visual Plasticity

Distinct circuits for recovery of eye dominance and acuity in murine amblyopia.
Stephany CÉ, Ma X, Dorton HM, Wu J, Solomon AM, Frantz MG, Qiu S, McGee AW. Curr Biol. 2018 Jun 18;28(12):1914-1923.

Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor.
McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM. Science. 2005 Sep 30;309(5744):2222-6.  
NEUROLOGY
Spinal Cord Injury (acute, subacute, chronic)

Nogo receptor decoy promotes recovery and corticospinal growth in non-human primate spinal cord injury. 
Wang X, Zhou T, Maynard GD, Terse PS, Cafferty WB, Kocsis JD, Strittmatter SM. Brain. 2020 Jun 1; 143(6):1697-1713.

Inhibiting an inhibitor: a decoy to recover dexterity after spinal cord injury.
Bradbury EJ, Oliveira R. Brain. 2020 Jun 1;143(6):1618-1622.

Human NgR-Fc decoy protein via lumbar intrathecal bolus administration enhances recovery from rat spinal cord contusion.
Wang X, Yigitkanli K, Kim CY, Sekine-Komo T, Wirak D, Frieden E, Bhargav A, Maynard G, Cafferty WB, Strittmatter SM. J Neurotrauma. 2014 Dec 15; 31(24):1955-66.

Recovery from chronic spinal cord contusion after Nogo receptor intervention.
Wang X, Duffy P, McGee AW, Hasan O, Gould G, Tu N, Harel NY, Huang Y, Carson RE, Weinzimmer D, Ropchan J, Benowitz LI, Cafferty WB, Strittmatter SM. Ann. Neurol. 2011 Nov;70(5):805–821.

Blockade of Nogo receptor ligands promotes functional regeneration of sensory axons after dorsal root crush.
Harvey PA, Lee DH, Qian F, Weinreb PH, Frank E. J Neurosci. 2009 May 13;29(19):6285-95.

Delayed Nogo receptor therapy improves recovery from spinal cord contusion.
Wang X, Baughman KW, Basso DM, Strittmatter SM. Ann Neurol. 2006 Nov;60(5):540-9.

Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. 
Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM. J Neurosci. 2004 Nov 17;24(46):10511-20.
Stroke

Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity.
Lee JK, Kim JE, Sivula M, Strittmatter SM. Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci. 2004 Jul 7;24(27):6209-17.
​​Multiple Sclerosis

Limiting neuronal Nogo Receptor 1 signaling during experimental autoimmune encephalomyelitis preserves axonal transport and abrogates inflammatory demyelination.
Lee JY, Kim MJ, Thomas S, Oorschot V, Ramm G, Aui PM, Sekine Y, Deliyanti D, Wilkinson-Berka J, Niego B, Harvey AR, Theotokis P, McLean C, Strittmatter SM, Petratos S. J Neurosci. 2019 Jul 10;39(28):5562-5580.

Can we design a Nogo receptor-dependent cellular therapy to target MS?
Kim MJ, Kang JH, Theotokis P, Grigoriadis N, Petratos S. Cells. 2018 Dec 20;8(1):1.

​Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.
Petratos S, Ozturk E, Azari MF, Kenny R, Lee JY, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, Siatskas C, Litwak S, Fehlings MG, Strittmatter SM, Bernard CC. Brain. 2012 Jun;135(Pt 6):1794-818.